Q1 Earnings Estimate for TSE:MDP Issued By Ventum Cap Mkts

Medexus Pharmaceuticals Inc. (TSE:MDP) – Investment analysts at Ventum Cap Mkts increased their Q1 2026 earnings per share estimates for Medexus Pharmaceuticals in a report issued on Wednesday, January 22nd. Ventum Cap Mkts analyst M. Czmielewski now forecasts that the company will earn ($0.09) per share for the quarter, up from their previous estimate of ($0.10). Ventum Cap Mkts currently has a “Strong-Buy” rating on the stock. The consensus estimate for Medexus Pharmaceuticals’ current full-year earnings is $0.16 per share. Ventum Cap Mkts also issued estimates for Medexus Pharmaceuticals’ Q2 2026 earnings at ($0.06) EPS, Q3 2026 earnings at ($0.01) EPS, Q4 2026 earnings at $0.03 EPS and FY2026 earnings at ($0.12) EPS.

MDP has been the subject of a number of other reports. Stifel Nicolaus upped their price target on Medexus Pharmaceuticals from C$4.15 to C$4.50 in a research note on Tuesday, January 14th. Raymond James upgraded shares of Medexus Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a C$4.00 target price on the stock in a report on Wednesday, January 8th. Leede Financial raised shares of Medexus Pharmaceuticals from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, January 22nd. Finally, Alliance Global Partners raised Medexus Pharmaceuticals to a “strong-buy” rating in a research note on Monday, December 23rd. One equities research analyst has rated the stock with a buy rating and five have issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Strong Buy” and a consensus price target of C$5.58.

Medexus Pharmaceuticals Trading Up 10.1 %

Shares of TSE:MDP opened at C$4.92 on Monday. The stock has a market capitalization of C$120.69 million, a P/E ratio of 98.40 and a beta of 1.96. The business has a 50-day moving average price of C$3.25 and a two-hundred day moving average price of C$2.72. Medexus Pharmaceuticals has a 1-year low of C$1.47 and a 1-year high of C$5.56.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.